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formance liquid chromatography coupled to tandem mass spectrometry (UHPLC-MS/MS) was successfully de-
veloped and validated for the analysis of 26 pharmaceutical compounds belonging to different therapeutic
classes (anorexics, stimulants, anxiolytics, antidepressants and laxatives), which are all prone to be illegally
added into weight-loss plant food supplements (PFS) for their pharmacological activity. Internal standard cali-
brationwith six isotopically labelled compounds rendered good linearity in the range of 5 to 1000 μg/l, depending
on the compound, and good sensitivity with limits of quantiﬁcation in the range of 0.02–9.80 μg/l. Recoveries
were assessed for all the 16 samples analysed andwere foundbetween 70%and 120% for over 90% of the analytes.
The average recovery value was 90.8%, for the different studied matrices (liquids, liquid ampoules, tablets and
capsules), with RSD values lower than 10% for all forms. The changes introduced to the QuEChERS procedure
maintained the good performance characteristics of the extractionmethodwhile preserving the chromatograph-
ic system for the introduction of unwantedmatrix compounds. Synephrinewas the only compounddetected and
quantiﬁed in one sample, but at a very low concentration (768 μg/l) and its presence may be due to the plant ex-
tracts used in the formulation, as synephrine is known to be a natural constituent of Citrus aurantium amara. De-
spite none of the 16 evaluated samples were found to be adulterated by the illegal addition of the drugs included
in this work, the developed methodology can be very useful for monitoring the adulteration of weight-loss PFS.
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Over the last few years, the consumption of plant food supplements
(PFS) has been growing globally (Egan et al., 2011). Different factors
have beenpointed out to explain the commercial success of PFS, including
a risingmistrust in pharmaceutical drugs, a higher demand for plant prod-
ucts and alternative therapies, and a rising tendency for self-medication
(Egan et al., 2011; Vargas-Murga et al., 2011). Moreover, because PFS
have plants or plant extracts as ingredients, they are often marketed as
being “natural” products, which are generally perceived by many con-
sumers as being safe and “healthier” than conventional pharmaceutical
drugs (Rocha et al., 2016). Although severalmedicinal plants are frequent-
ly included in the formulationof PFS, theseproducts are legally considered
as foods both in the European Union (EU) and the United States of Amer-
ica (USA), underDirective 2002/46/EC (European Commission, 2002) and
the Dietary Supplement Health and Education Act (DSHEA), respectively.Therefore, both in the EU and USA, PFS do not require any safety assess-
ment prior to their commercialization, with the responsibility for food
safety issues relying on food business operators (Silano et al., 2011).
Among the several problems that may affect the safety of PFS, adul-
teration by the illegal addition of pharmaceutical drugs represents a
public health concern of major importance. Over the last years, an in-
creasing number of tainted PFS has been reported by the Food and
Drug Administration (FDA) and by the European Rapid Alert System
on Food and Feed (RASFF), with PFSmarketed for enhancing sexual per-
formance and for losingweight being themost frequent targets of adul-
teration (Rocha et al., 2016).
Since overweight currently affects millions of individuals world-
wide, weight-loss products are undoubtedly one of the most popular
type of PFS, particularly in the Western societies where slim ﬁgures
are generally promoted, either for healthy or aesthetic motives.
Weight-loss PFS are frequently advertised as products providing rapid
slimming effects, thus representing easy solutions to lose weight com-
pared to changes in eating behaviour and lifestyle/exercising. To pro-
mote their effectiveness and increase sales, unscrupulous producers
can dope PFS with pharmaceutical drugs to provide for quick results in
order to satisfy consumer's expectations. The adulterant drugsmost fre-
quently associatedwithweight-loss PFS are anorexics derived from am-
phetamines, including several substances previously used as medicines
for the treatment of overweight and obesity, such as sibutramine
(Meridia® and Reductil®), fenﬂuramine (Ponderax®) and rimonabant
(Acomplia®). The use of these drugs is currently banned by the FDA
and the EuropeanMedicines Agency (EMA) due to potential risks of se-
vere side effects, such as cardiovascular events. The use of other am-
phetamine-like anorexics, such as amfepramone and fenproporex, has
also been reported since they are able to induce appetite loss, increase
satiety and reduce intestinal fat absorption. According to Carvalho et
al. (2011), other substances from different pharmaceutical classes,
such as stimulants, anxiolytics, antidepressants and laxatives, are also
prone to be illegally added to PFS. Besides anorexics, undeclared stimu-
lants, including ephedrine, synephrine and methamphetamine, can be
added to weight-loss PFS as they increase thermogenesis and induce
loss of appetite. On the other hand, anxiolytics, such as benzodiazepines,
can be added tomask the stimulating/euphoria effects of amphetamine-
derived anorexics and stimulants, and simultaneously contribute to
diminishing anxiety, which is characteristically present in many obese
patients (Carvalho et al., 2011). Moreover, it has been demonstrated
that obesity and depression have a bidirectional relationship, meaning
that obesity increases the risk of depression, especially in women, as
well as depression increases the risk of overweight and obesity
(Luppino et al., 2010). Therefore, antidepressants are also prone to be il-
legally added toweight-loss supplements, as reported by Cohen (2009)
who described a case report of a 38-years old man using diet pills
imported into the USA that were found to be adulterated with
fenproporex and ﬂuoxetine, after an occupational urine control positive
for amphetamine. Finally, due to its pharmacological activity, the pres-
ence of laxatives has also been frequently reported in public notiﬁca-
tions from the FDA and RASFF, in particular phenolphthalein, a drug
used over a century to treat constipation but withdrawn from market
in 1997 due to carcinogenicity concerns (Coogan et al., 2000).
Presently, hyphenated techniques, namely liquid chromatography
coupled to tandem mass spectrometry (LC–MS/MS) are considered
techniques of choice for the determination and quantiﬁcation of phar-
maceutical drugs in PFS, both because of the complexity of the matrix
and due to its high selectivity and sensitivity (Liang et al., 2006;
Vaclavik et al., 2014a; Vaclavik et al., 2014b). At the same time, nowa-
days the trend goes toward the use of ultra-high performance liquid
chromatography (UHPLC), which uses short, narrow bore columns,
packed with particles with a lower diameter (sub-2 μm), allowing for
a faster analysis, better resolution andnarrower peaks compared to con-
ventional HPLC methodologies (Paíga et al., 2015).
Therefore, the aimof thisworkwas to develop an analyticalmethod-
ology using UHPLC-MS/MS for the quantiﬁcation of 26 pharmaceutical
drugs belonging to different therapeutic classes (anorexics, stimulants,
anxiolytics, antidepressants and laxatives), which are all prone to be il-
legally added into weight-loss PFS for their pharmacological activity.
Two anticonvulsants were also included in the study, namely
topiramate, which is approved to be used with fentermine for long
term weight-management, and zonisamide since a combination of this
compound together with bupropion is currently under clinical trials to
be used as a treatment for obesity (FDA, 2012; Ioannides-Demos et al.,
2011). The Quick, Easy, Cheap, Effective, Rugged, and Safe (QuEChERS)
method was used for sample extraction based on a modiﬁcation of the
method proposed by Vaclavik et al., 2014b.
2. Material and Methods
2.1. Reagents and Materials
Acetonitrile and methanol for LC-MS were supplied by J.T. Baker
(Deventer, Netherlands). Ultra-pure water (18.2 MΩ cm−1) wasproduced using a Simplicity 185 system (Millipore, Molsheim, France).
All chromatographic solvents were ﬁltered through a 0.22 μm nylon
membrane ﬁlter (Supelco, Bellefonte, PA, USA) using a vacuum pump
(Dinko D-95, Barcelona, Spain) and degassed for 15min in an ultrasonic
bath (Sonorex Digital 10P, BANDELIN, Germany). Formic acid (≥95%),
ammonium formate (≥99.9%), anhydrous magnesium sulphate (≥
99.5%) and sodium chloride (≥99.5%) were purchased from Sigma-Al-
drich (St. Louis, MO, USA). QuEChERS (4 g MgSO4 and 1 g NaCl) were
obtained from Agilent Technologies (Santa Clara, CA, USA).
All pharmaceutical standards were of high purity grade (≥98.5%).
Clobenzorex hydrochloride, fenﬂuramine hydrochloride, rimonabant,
sibutramine hydrochloride, synephrine, and zonisamide were pur-
chased from LGC (Middlesex, UK). Alprazolam, amfepramone hydro-
chloride, bupropion hydrochloride, D-cathine hydrochloride,
diazepam, (+)-ephedrine hydrochloride, fentermine hydrochloride,
lorazepam, mazindol, D,L-methamphetamine hydrochloride, D,L-
norephedrine hydrochloride, and topiramate were purchased from
Lipomed AG (Arlesheim, Switzerland).
Topiramate-d12 in methanol solution was purchased from LGC
(Middlesex, UK), diazepam-d5 and D,L-methamphetamine-d5 hydro-
chloride were acquired from Lipomed AG (Arlesheim, Switzerland).
Carbamazepine-d10, diazepam-d5, ﬂuoxetine-d5, D,L-methamphet-
amine-d5 and venlafaxine-d6were the isotopically labelled compounds
used as internal standards in electrospray ionization (ESI) (+) whereas
topiramate-d12was used in ESI (−) analysis.
Both individual stock standard and isotopically labelled internal
standard solutions (at a concentration of 1000 mg/l) were prepared
on a weight basis in methanol. Working standard solutions containing
all pharmaceuticals were prepared in acetonitrile-ultra-pure water
(5:95, v/v) by mixing appropriate amounts of the stock solutions.
These solutions were prepared before each analytical run.
2.2. Samples
Sixteen PFS sampleswere purchased frompharmacy stores, internet
vendors or supplied by their producers. Most of the PFS were intended
for weight loss purposes and two were St. John's wort based PFS. The
analysed samples were in the form of capsules, liquids, ampoules, and
tablets. A detailed description of the PFS samples is given in Table S1
(Supplementarymaterial). The solid PFSwere thoroughly homogenized
before analysis.
2.3. Sample Preparation
Amodiﬁcation of the QuEChERS method proposed by Vaclavik et al.
(2014b)was used for sample extraction. The capsuleswere opened and
their content homogenized while tablets were homogenized using a
mortar and pestle.
An aliquot of 0.50 ± 0.01 g of homogenized sample, in the case of
tablets and capsules, or 5 ml, in the case of liquids, were measured
into a 50 ml polypropylene (PP) centrifuge tube. For recovery studies,
spiking solution was added, the mixture was vortexed and rested for
30 min. Then, 10 ml (for solid samples) or 5 ml (for liquid samples) of
water containing 0.1% formic acid were added, vortexed for 1 min and
incubated for 30 min under ambient conditions. Afterwards, 10 ml of
acetonitrile were added, vortexed for 1 min and shaken for 30 min at
100 rpm in an orbital shaker AO-400 (Bunsen S.A., Madrid, Spain).
Then, 4 g of anhydrous MgSO4 and 1 g of NaCl were added to the tube.
The sample was vortexed for 1 min and centrifuged for 7 min at
1448g. An aliquot of 1 ml of the acetonitrile extract was evaporated to
dryness, re-dissolved in 1 ml of acetonitrile:water (80:20%, v/v),
vortexed and ﬁltered through a 0.22 μmPTFE ﬁlter. 500 μl of the extract
were diluted with 1 ml of acetonitrile:water (10:90%, v/v) and left for
1 h in the refrigerator. If precipitation occurs, themixture is centrifuged
for 7 min at 1448g, ﬁltered through a 0.22 μm PTFE and analysed by
UHPLC-MS/MS. Isotopically labelled compounds were added to
standard solutions and sample extracts in order to obtain the following
concentrations: carbamazepine-d10: 15 μg/l; diazepam-d5: 60 μg/l; ﬂu-
oxetine-d5: 15 μg/l; D,L-methamphetamine-d5: 100 μg/l; topiramate-
d12: 100 μg/l and venlafaxine-d6: 30 μg/l.
2.4. UHPLC–MS/MS Analysis
Analysis was carried out on a UHPLC–MS/MS system consisting of a
Shimadzu Nexera UHPLC system (Shimadzu Corporation, Kyoto, Japan)
equipped with two solvent delivery modules LC–30 AD, a column oven
CTO–20 AC, and an auto-sampler SIL–30 AC, coupled to a Shimadzu
LCMS–8030 triple-quadrupole mass spectrometer (Shimadzu Corpora-
tion, Kyoto, Japan) operated in the electrospray ionization (ESI) mode.
The system was controlled by a CBM–20A module. Lab Solutions soft-
ware (Shimadzu Corporation, Kyoto, Japan) was used for control and
data processing.
Chromatographic separation was achieved in a Kinetex C18 column
(150 × 2.6mm; 1.7 μmparticle size) (Phenomenex, USA). The injection
volume was 5 μl and column oven was set at 30 °C. The auto-sampler
was operated at 4 °C and the needle was rinsed before and after sample
aspiration using acetonitrile:methanol:propanol (1:1:1, v/v/v).
In order to optimize the chromatographic separation and sensitivity
of the studied analytes, differentmobile phases and additiveswere test-
ed. Acetonitrile was used as organic phase, while non-buffer ultra-pure
water, 5mMammoniumacetate (pH 4) buffer solution, and 0.1% formic
acid solution were evaluated as aqueous phases. Once themobile phase
composition was established, the elution mode (isocratic or gradient),
as well as the ﬂow rate were optimized with the aim to improve chro-
matographic resolution and peak shapes, and simultaneously to reduce
total analysis time.
Two different gradient programs were used, one for ESI (+) and the
other for ESI (−) modes. The optimized ESI (+)mobile phase consisted
of ultra-pure water containing 0.1% formic acid (eluent A) and acetoni-
trile (eluent B). The gradient elutionwas performed as follows: 0–1min
eluent B 5%; 1–6.50 min eluent B 5%–100%; 6.50–7.50 min eluent B
100%; 7.50–8.50 min eluent B 100%–5%; column equilibration 8.5–
11 min eluent B 5% (ﬂow rate 0.3 ml min−1). The ESI (−) mobile
phase consisted of ultra-pure water (eluent A) and acetonitrile (eluent
B), and the gradient elution was as follows: 0–5.50 min eluent B 10%–
100%; 5.50–6.50 min eluent B 100%–10%; column equilibration 6.5–
9 min eluent B 10% (ﬂow rate 0.3 ml min−1).
MS settings were analyte-speciﬁc and were optimized by direct in-
jection of individual standard solutions (10mg/l). Themass spectrome-
terwas operated inmultiple reactionmonitoringmode (MRM) and two
MRM transitions were monitored for each compound, being the most
intense used as quantiﬁer and the second one as qualiﬁer. A dwell
time of 15 ms was used for all compounds in the positive mode and
100 ms for the compounds in the negative mode.
Source-dependent parameters were also optimized by direct injec-
tion, using a standard mixture solution (10 mg/l), and were as follows:
nebulizing gas (nitrogen) and drying gas (nitrogen) at a ﬂow rate of 2.6
and 15.0 l min−1 , respectively; interface voltage was set at 5.0 kV;
desolvation temperature was 300 °C, and heat block temperature was
425 °C. Argon was used as the collision induced dissociation gas (CID)
at a pressure of 230 kPa. Optimization was performed based on the
sum of the areas of all peaks obtained within the speciﬁed variable
ranges tested (interface voltage (IV): 0.2–5.0 kV; nebulizing gas ﬂow:
0.5–3.0 l min−1; drying gas ﬂow: 10–20 l min−1; desolvation line tem-
perature: 200–300 °C, and heat block temperature: 200–500 °C).
2.5. Validation of the Method
The method was validated through the estimation of the linearity,
detection (LOD) and quantiﬁcation limits (LOQ), repeatability and re-
producibility, extraction recoveries, and matrix effects.Calibration curves were obtained by linear regression analysis over
the established concentration levels in the range of 5 to 1000 μg/l, de-
pending on the compound. Quantiﬁcation of the target analytes was
performed by the internal standard approach. LODs and LOQs were cal-
culated by the software as the minimum detectable amount of analyte
with a signal-to-noise (S/N) of 3 and 10, respectively.
The intra-day precision was determined by analysis of a 100 μg/l
mixed standard solution six times within a single day, and the inter-
day precision was assessed by the analysis of the standard solution on
three consecutive days. Precisionwas expressed as the relative standard
deviation (RSD) of the replicates.
Matrix effects were assessed in order to evaluate, for each analyte,
the degree of ion suppression or enhancement. Matrix effects were cal-
culated as the ratio of the peak area of a standard spiked in a blank ma-
trix and the same standard concentration prepared in solvent (the
mobile phase). A value of 100% indicates that there is no matrix effect,
while values higher than 100% reﬂect ion enhancement and values
lower than 100% ion suppression.
Recoveries were calculated as the ratio between the concentrations
calculated using internal standard calibration, and the initial spiking
levels. Recovery tests were performed at a single fortiﬁcation level, for
all the different samples analysed. For each recovery experiment, blanks
(unspiked samples) were previously analysed for the presence of the
analytes. With the exception of one sample, none of the studied com-
pounds was determined in the blanks.
3. Results and Discussion
3.1. Optimization of UHPLC-MS/MS Parameters
The identiﬁcation of precursor and product ions, and preliminary op-
timization of the instrument settings were performed using individual
compound solutions prepared in acetonitrile (100 mg/l). Mass transi-
tions and MS/MS parameters were optimized in order to attain the
best speciﬁcity and sensitivity. Analyte's MRM transitions were moni-
tored in thepositive and negative ESImodes.Most of the compounds in-
cluded in this study formed ions under positive mode ESI conditions.
The majority of the analytes (23) provided intense [M + H]+ ions
(Table 1), while zonisamide, phenolphthalein, topiramate, and
topiramate-d12 were analysed in the negative ionization (ESI) mode,
as [M−H]− ions (Table 1). For most compounds, twoMRM transitions
from the ionizedmolecule of the target compoundweremonitored. The
most abundant product ion was used for quantiﬁcation and the second
transition was used as qualiﬁer. For the isotopically labelled internal
standards only one MRM was monitored since they are not likely to
be found in the PFS samples. Of the 23 analytes studied, 11 compounds
have been previously analysed by Vaclavik et al. (2014b) under ESI (+)
in a Q Exactive quadrupole–orbitrap mass spectrometer. In our study,
using a triple quadrupole MS/MS equipment, those compounds were
also analysed in ESI (+) with the exception of topiramate, which was
analysed under ESI (−), and they all produced at least one or two of
the ions listed by Vaclavik et al. (2014b). Product ion mass spectra for
the different compounds are shown in Figs. S.1 and S.2 (Supplementary
materials). Once the most appropriate ions have been selected, ioniza-
tion parameters including drying and nebulizing gas ﬂow rates, heat
block and desolvation temperatures and interface voltage were opti-
mized as described in materials and methods section, since they are
known to be key parameters to obtain higher sensitivity. Figs. S.3 to
S.7 (Supplementary materials) present the data used for optimization
of the source-dependent parameters regarding all analytes with the ex-
ception of the antidepressants and diazepam, for which optimization
data was obtained in a previous work (Santos et al., 2016).
When analysing complex matrices, such as PFS, a chromatographic
step preceding the ionization and mass analysis of the analyte mole-
cules is of major importance since it enables the separation of com-
pounds that can interfere or supress the signals of the analytes of
Table 1
Optimized MS/MS conditions for the selected compounds analysed in the positive and negative electrospray ionization (ESI) mode.
Number Compound Precursor ion Product 1 Product 2 Ion ratio
m/z Q1
Pre Bias
(V)
CE Q3
Pre Bias
(V)
m/z Q1
Pre Bias
(V)
CE Q3
Pre Bias
(V)
ESI (+)
1 Alprazolam 309.10 [M + H]+ 281.05 −14 −27 −19 204.95 −14 −44 −22 1.22
2 Amfepramone 205.50 [M + H]+ 105.10 −30 −30 −20 100.15 −30 −25 −19 1.14
3 Bupropion 239.50 [M + H]+ 183.85 −30 −17 −21 131.15 −30 −18 −13 1.11
4 Carbamazepine 236.95 [M + H]+ 194.10 −21 −20 −13 193.10 −21 −35 −13 4.91
5 Cathine 151.70 [M + H]+ 134.10 −16 −14 −13 117.10 −16 −21 −23 2.33
6 Citalopram 324.85 [M + H]+ 109.20 −30 −26 −22 262.20 −30 −19 −18 3.77
7 Clobenzorex 259.50 [M + H]+ 91.10 −30 −30 −17 119.15 −30 −16 −12 2.29
8 Diazepam 284.75 [M + H]+ 154.05 −27 −29 −15 193.05 −27 −33 −13 1.20
9 Ephedrine 165.50 [M + H]+ 148.15 −30 −19 −15 91.10 −30 −33 −17 3.35
10 Fenﬂuramine 231.50 [M + H]+ 159.05 −30 −23 −16 109.15 −30 −45 −21 3.05
11 Fentermine 149.50 [M + H]+ 91.10 −28 −21 −18 65.05 −28 −42 −12 5.48
12 Fluoxetine 310.25 [M + H]+ 44.25 −11 −14 −16 148.15 −11 −10 −15 13.17
13 Lorazepam 320.90 [M + H]+ 274.90 −16 −22 −19 302.90 −16 −17 −21 2.01
14 Mazindol 285.10 [M + H]+ 43.70 −13 −30 −30 18.05 −13 −55 −19 18.70
15 Methamphetamine 149.50 [M + H]+ 91.10 −30 −21 −17 119.10 −30 −16 −23 4.62
16 Norephedrine 151.60 [M + H]+ 134.10 −30 −15 −14 117.15 −30 −21 −11 2.28
17 Paroxetine 330.00 [M + H]+ 70.20 −22 −33 −13 44.15 −22 −26 −17 1.54
18 Rimonabant 462.50 [M + H]+ 362.90 −30 −29 −25 84.10 −30 −27 −16 3.42
19 Sertraline 306.15 [M + H]+ 275.10 −28 −13 −19 159.05 −28 −29 −16 0.89
20 Sibutramine 279.50 [M + H]+ 125.10 −30 −24 −12 139.10 −30 −17 −14 1.81
21 Synephrine 167.70 [M + H]+ 150.10 −16 −12 −15 91.10 −16 −23 −18 4.09
22 Trazodone 371.85 [M + H]+ 176.10 −30 −26 −18 148.15 −30 −36 −15 1.21
23 Venlafaxine 277.90 [M + H]+ 58.20 −30 −21 −10 260.30 −30 −13 −18 5.66
24 Carbamazepine-d10 247.15 [M + H]+ 204.15 −23 −22 −14
25 Diazepam-d5 290.10 [M + H]+ 154.05 −13 −29 −10
26 Fluoxetine-d5 315.15 [M + H]+ 44.25 −11 −14 −16
27 D,L-Methamphetamine-d5 154.50 [M + H]
+ 92.10 −30 −21 −18
28 Venlafaxine-d6 283.50 [M + H]+ 64.05 −30 −21 −11
ESI (−)
29 Phenolphthalein 317.10 [M−H]− 93.05 20 13 18 273.00 20 23 20 6.85
30 Topiramate 338.10 [M−H]− 77.85 23 27 15 96.05 23 25 19 6.82
31 Zonisamide 211.10 [M−H]− 118.95 13 15 24 147.05 13 10 30 1.66
32 Topiramate-d12 350.20 [M−H]− 77.90 22 31 15
CE – Collision energy.interest and, when standards are available, allows for the comparison of
retention times. Therefore, despite the mass selectivity of the detector,
baseline separation of the analytes is always preferred in LC–MS
(Vaclavik et al., 2014a). In this work, chromatographic conditions
were optimized regarding mobile phase composition and gradient to
improve the resolution of compounds and peak shape in the shortest
analysis time. Differentmobile phases comprising several combinations
of organic solvents and water were tested using isocratic and gradient
elution. Of the several mobile phases tested in ESI (+), including aceto-
nitrile, water, 0.1% formic acid solution, and 5 mM ammonium acetate
buffer (pH = 4), best chromatographic performance was achieved
using 0.1% formic acid and acetonitrile, which were consequently cho-
sen as mobile phase. The effect of the initial organic solvent percentage
was tested in the range of 5–30%, and the best results were obtained
using the lowest value. In ESI (+), the retention times of the 28 com-
pounds (23 analytes and 5 isotopically labelled compounds used as
internal standards) were b8 min, with a total run time of 12 min
(Fig. 1). In ESI (−), water and acetonitrile were used in gradient
mode, allowing the analysis of 3 compounds and one internal standard
in b5 min (Fig. 2).
3.2. QuEChERS Extraction
As discussed by Vaclavik et al. (2014a) in a recent review paper on
the MS analysis of pharmaceutical adulterants in PFS, analytes' extrac-
tion is mostly accomplished using organic solvents, namely, methanol
and acetonitrile. Homogenized solid samples are usually extracted by
means of shaking and/or sonication while liquid samples are frequentlydiluted with the solvent. These procedures are considered simple and
relatively rapid, however in complexmatrices, such as PFS, have the dis-
advantage of frequently co-isolate high amounts of matrix components
that can potentially interfere with the detection of target analytes and
cause severe matrix effects in MS analysis (Vaclavik et al., 2014a;
Vaclavik et al., 2014b). Although QuEChERS extraction can overpass
such inconvenient, this approach has not been frequently used in PFS
analysis. The exception is the work performed by the same group of au-
thors, where QuEChERS were employed for the analysis of 96 pharma-
ceuticals, plant toxins, and other plant secondary metabolites in PFS.
In the present work, the QuEChERS method used for sample extraction
was based on a modiﬁcation of the reported method (Vaclavik et al.,
2014b), which included the analysis of the acetonitrile layer, directly
or after dilution with pure acetonitrile, using 10 to 10,000 dilution fac-
tors aiming to eliminate matrix effects (Vaclavik et al., 2014b). Howev-
er, our experimental conditions did not allow the use of such high
dilution factors. Additionally, for many samples, large amounts of sam-
ple components were transferred to the acetonitrile extract, that were
not soluble in the initial composition of the mobile phase used in the
gradient (5% of acetonitrile), and precipitate in the chromatographic
column. Therefore, modiﬁcations to the sample extraction procedure
were introduced in order to avoid this situation, namely an aliquot of
1 ml of the acetonitrile layer was evaporated to dryness and re-dis-
solved in 1 ml of acetonitrile:water (80:20%, v/v), since a high percent-
age of organic solvent is needed to increase the solubility of the analytes
in the solution. Afterwards, 500 μl of the extract were combined with
1 ml of acetonitrile:water (10:90%, v/v) in order to increase the water
content of the extract before analysis, and also to assess if precipitation
Fig. 1. Overlay chromatograms of the compounds analysed in ESI (+) mode (For peak identiﬁcation refer to Table 1).
Fig. 2. Overlay chromatograms of the compounds analysed in ESI (−) mode (For peak identiﬁcation refer to Table 1).
occurs for this new solvent composition. This modiﬁcation allowed the
analysis of the different types of samples (liquids, tablets and capsules)
with good recoveries, as will be discussed in the next section, while
avoiding the introduction of unwanted sample components in the chro-
matographic column and MS detector.3.3. Method Validation
The validation parameters of the UHPLC-MS/MS method are pre-
sented in Table 2. Under the optimized conditions, standard mixtures
were analysed to obtain calibration curves based on the linear regres-
sion analysis of the peak area versus concentration, using appropriate
internal standards. Calibration curves with nine calibration levels in
the range 5–1000 μg/l were tested for all the compounds. Depending
on the analyte, some levels were excluded in order to improve linearity.
Calibration parameters (slope, intercept, and coefﬁcient of determina-
tion) were automatically obtained from the software. With the excep-
tion of trazodone (0.9984) and clobenzorex (0.9979), all the
determination coefﬁcients (R2) were higher than 0.999 (Table 2). Chro-
matograms of individual standard solutions of topiramate and
sibutramine as well as the corresponding calibration curves are shown
in Figs. S.8 to S.11 (Supplementary materials), as examples.
LODs and LOQs were in the range 0.01–2.94 μg/l and 0.02–9.80 μg/l,
respectively, showing an adequate sensitivity to detect possible adulter-
ations by the illegal addition of these drugs to PFS.
Intra-day precision (expressed as coefﬁcient of variation) ranged
from0.9% to 6.4%, for carbamazepine-d10 andﬂuoxetine-d5, respective-
ly, with an average value of 3.3%. Inter-day precisionwas in the range of
0.5 to 11.4%, for clobenzorex and synephrine, respectively, with a mean
value of 5.9%.
Matrix effects were assessed using a mixed standard solution which
was evaporated to dryness and re-dissolved inmatrix extract.Matrix ef-
fects, estimated as the ratio of the obtained peak area and theone for the
standard in solvent are shown on Table 3. The lowest value wasTable 2
Validation parameters of the developed UHPLC-MS/MS method for the compounds analysed in
Compound tr (min) IS Calibration equation
ESI (+)
Synephrine 1.344 M Y = 0.758789X + 0.02293
Cathine 3.786 M Y = 1.54181X− 0.024969
Norephedrine 3.786 M Y = 1.25304X− 0.023279
Methamphetamine 3.786 M Y = 1.90389X + 0.059723
Ephedrine 3.939 M Y = 0.806934X + 0.28671
Phentermine 4.200 M Y = 4.49850X + 0.104529
Amfepramone 4.282 M Y = 0.869667X + 0.02310
Venlafaxine 4.822 V Y = 6.89422X− 0.12992
Bupropion 4.840 M Y = 0.589020X + 0.01477
Mazindol 4.864 M Y = 3.68487X− 0.022563
Trazodone 4.900 F Y = 0.832830X + 0.71192
Fenﬂuramine 4.950 M Y = 0.477972X − 0.03141
Citalopram 5.154 F Y = 1.20743X + 0.117510
Clobenzorex 5.172 M Y = 1.30241X− 0.016542
Paroxetine 5.282 F Y = 0.614295X − 0.07156
Fluoxetine 5.486 F Y = 1.03079X + 0.137943
Carbamazepine 5.511 C Y = 1.62729X + 0.040370
Sertraline 5.546 F Y = 0.482933X + 0.11343
Sibutramine 5.628 M Y = 1.42670X− 0.084465
Lorazepam 5.684 M Y = 0.292740X − 0.01789
Alprazolam 5.687 M Y = 0.417668X − 0.03910
Diazepam 6.249 D Y = 0.612050X + 0.03045
Rimonabant 7.789 M Y = 0.360945X − 0.00218
ESI (−)
Zonisamide 3.658 T Y = 1.79851X + 0.117548
Topiramate 4.185 T Y = 1.34519X− 0.010693
Phenolphthalein 4.483 T Y = 7.12323X + 0.553430
IS – Internal standard; C: Carbamazepine-d10; D: Diazepam-d5; F: Fluoxetine-d5; M: D,L-Methobserved for citalopram in a capsule sample (60.2%), and the highest
was found for carbamazepine in a liquid sample (145.0%).
Recovery results for all the matrices analysed are presented in Table
4. QuEChERS recovery was calculated as the ratio of the estimated con-
centrations obtained for the fortiﬁed samples and the theoretical
amount used for spiking. The lowest recovery was obtained for
citalopram in a capsule sample (54.9%) and the highest was found for
amfepramone in a liquid sample (130.5%). Considering all the samples,
acceptable recoveries between 70% and 120% were obtained for over
90% of the analytes. The average recovery value obtained for all the ma-
trices and analytes was 90.8%, which indicates a good performance of
the method for the different studied matrices (liquids, liquid ampoules,
tablets and capsules), with RSD values lower than 10% for all forms. The
lowest recovery values, in the range 54.9–69.0%, were obtained only for
8.56% of the combinations of analytes/samples tested and were mainly
related to cathine, norephedrine, and synephrine, which are some of
the most water soluble compounds studied.
3.4. Application to Real Samples
Although previous studies have been reported on the detection of
pharmaceutical substances in PFS marketed for weight-loss, most are
restricted to the evaluation of a few drugs, mainly comprising anorexics
and stimulants (Cianchino et al., 2008; Reeuwijk et al., 2014; Zeng et al.,
2016). Otherworks refer to PFS in general and, therefore, include a great
number of substances of different classes including analgesics, anti-dia-
betics, aphrodisiac drugs, blood pressure and cholesterol-lowering
drugs, anti-inﬂammatory drugs and plant toxins, among others
(Bogusz et al., 2006; Chen et al., 2009; Johansson et al., 2014; Kim et
al., 2009; Vaclavik et al., 2014b), which are of few interest when specif-
ically considering weight-loss PFS. In this work, as a more effective ap-
proach toward the detection of adulterated PFS marketed for weight
loss, the substances of interest were selected on the basis of their suit-
ability to be used as adulterants for their pharmacological activities.
Therefore, different drugs including anorexics, stimulants,the ESI (+) and ESI (−) modes listed by retention time.
Calibration range
(μg/l)
R2 LOD
(μg/l)
LOQ
(μg/l)
80 5–250 (n = 6) 0.9994 0.53 1.75
3 5–1000 (n = 9) 0.9992 0.76 2.54
5 5–250 (n = 7) 0.9997 0.46 1.54
8 5–250 (n = 7) 0.9995 0.23 0.77
7 5–250 (n = 7) 0.9993 0.49 1.62
5–250 (n = 6) 0.9994 0.19 0.63
53 5–250 (n = 7) 0.9985 0.41 1.35
3 5–750 (n = 8) 0.9999 0.08 0.28
55 5–250 (n = 6) 0.9995 0.39 1.29
9 5–750 (n = 9) 0.9995 2.94 9.8
8 5–250 (n = 7) 0.9984 0.10 0.32
84 5–1000 (n = 9) 0.9999 1.97 4.95
5–500 (n = 8) 0.9999 0.08 0.25
4 5–250 (n = 7) 0.9979 0.45 1.51
92 5–500 (n = 8) 0.9988 0.23 0.77
5–1000 (n = 9) 0.9996 0.05 0.17
6 5–1000 (n = 9) 0.9998 0.11 0.35
7 5–500 (n = 8) 0.9998 0.01 0.04
4 5–1000 (n = 10) 0.9992 0.51 1.7
89 5–250 (n = 7) 0.9994 0.17 0.58
36 5–1000 (n = 10) 0.9996 0.23 0.76
83 5–250 (n = 7) 0.9993 0.10 0.32
738 5–750 (n = 9) 0.9998 0.04 0.12
25–750 (n = 7) 0.9998 0.13 0.44
5 5–1000 (n = 10) 0.9998 0.12 0.42
10–500 (n = 7) 0.9995 0.01 0.02
amphetamine-d5; T: Topiramate-d12; V: Venlafaxine-d6.
Table 3
Matrix effect (%) for the different analytes and samples at a concentration of 250 μg/l.
Compound Liquid samples Liquid ampoule samples Tablet Capsule samples Mean
(%)
PFS2 PFS3 PFS4 PFS14 PFS15 PFS16 PFS5 PFS6 PFS11 PFS12 PFS13 PFS7 PFS1 PFS8 PFS9 PFS10
ESI (+)
Alprazolam 133.3 127.6 112.6 128.2 130.1 132.4 115.4 113.0 111.5 106.2 122.1 109.2 130.0 128.9 114.7 132.5 121.7
Amfepramone 69.2 72.3 76.8 70.5 67.3 62.8 72.2 64.6 72.5 71.3 71.8 75.0 80.7 66.8 77.6 80.3 72.0
Bupropion 85.7 78.9 104.7 88.4 93.8 98.2 92.0 86.0 104.0 94.0 88.6 97.1 83.5 90.1 94.6 105.1 92.8
Carbamazepine 145.1 132.5 132.4 140.2 145.0 142.7 133.9 129.6 135.2 131.2 144.0 137.5 133.9 126.3 137.1 141.6 136.8
Cathine 116.2 103.4 107.9 107.0 110.1 104.9 113.1 116.4 117.0 121.9 100.0 100.2 84.4 105.9 116.1 116.5 108.8
Citalopram 72.1 62.3 65.3 64.5 63.0 60.4 69.2 73.3 87.2 98.3 66.5 76.9 60.2 133.2 90.8 70.4 75.9
Clobenzorex 93.2 81.1 86.3 82.7 95.7 93.8 79.3 76.5 119.0 116.5 83.5 107.1 100.9 110.9 120.8 91.1 96.2
Diazepam 128.2 127.6 131.1 128.4 137.9 126.3 117.6 117.1 126.6 119.6 139.8 127.3 136.3 129.1 127.1 119.8 127.5
Ephedrine 120.8 72.2 112.3 105.6 108.8 111.0 98.7 79.6 124.5 121.3 102.0 127.6 94.7 103.6 115.3 113.5 107.0
Fenﬂuramine 86.3 92.0 114.5 93.5 88.6 91.3 81.1 83.2 119.2 105.5 99.9 83.5 93.3 87.4 107.4 113.2 96.2
Fluoxetine 110.0 111.7 103.6 105.0 95.9 88.6 97.8 101.2 127.3 123.9 105.1 105.6 82.1 109.4 122.9 116.3 106.7
Lorazepam 124.4 115.4 118.4 108.5 115.5 102.8 117.3 117.2 118.7 119.6 116.9 118.8 107.3 103.7 117.4 126.5 115.5
Mazindol 104.1 98.2 107.8 97.3 95.8 91.7 105.9 107.1 118.5 97.9 95.7 119.7 83.1 115.5 116.4 121.7 104.8
Methamphetamine 86.1 109.4 85.1 84.9 92.8 99.8 95.2 86.9 101.3 94.5 84.6 104.8 108.1 96.5 106.0 104.7 96.3
Norephedrine 107.8 92.6 105.0 96.3 93.9 92.6 100.8 102.3 101.9 107.4 93.0 91.7 89.7 94.3 102.2 106.5 98.6
Paroxetine 83.3 87.7 81.2 87.4 81.7 78.3 88.2 100.3 94.2 95.5 90.8 77.9 65.1 95.6 91.8 101.9 87.5
Phentermine 79.6 99.0 88.8 72.2 90.5 96.0 88.0 80.6 89.9 88.1 81.3 99.0 102.1 82.3 100.7 101.2 90.0
Rimonabant 110.0 129.6 126.0 114.5 125.8 127.0 108.6 111.0 109.9 116.3 123.8 119.3 60.6 120.4 112.1 119.6 114.7
Sertraline 108.7 97.5 98.4 97.8 95.1 80.1 109.0 112.6 117.3 120.4 96.2 105.7 84.7 88.1 113.6 116.2 102.6
Subitramine 89.4 96.7 106.6 100.8 96.3 95.3 89.8 97.5 97.7 99.3 108.0 97.8 71.2 93.7 94.6 97.6 95.8
Synephrine 72.1 89.8 97.9 111.7 134.7 74.9 135.6 93.0 79.2 137.1 129.1 69.9 80.6 74.4 88.4 115.3 99.0
Trazodone 114.4 101.5 122.8 104.3 122.3 109.3 101.4 100.6 112.7 105.2 112.5 125.4 122.1 128.3 133.4 104.1 94.1
Venlafaxine 108.9 106.7 102.7 112.2 120.8 116.9 100.7 107.4 109.1 90.2 113.8 127.5 107.7 137.4 109.7 102.6 113.8
ESI (−)
Phenolphthaleine 61.1 87.5 58.1 87.5 64.1 73.2 75.7 75.0 62.7 88.2 82.3 75.1 76.5 75.3 67.6 86.3 74.8
Topiramate 114.6 114.5 92.7 125.1 103.5 108.4 111.7 121.9 109.1 111.5 120.3 114.2 72.0 110.2 120.4 125.6 111.0
Zonisamide 106.2 138.7 97.6 139.7 123.3 121.4 133.1 139.1 97.1 90.4 134.5 69.8 61.7 62.7 86.4 137.6 108.7antidepressants, anxiolytics, a laxative and two anticonvulsants whose
use is associated with weight-loss, were selected. As far as we know,
this is the ﬁrst study reporting a methodology for the detection of
some compounds (citalopram, fentermine, trazodone, venlafaxine and
zonisamide) in PFS, and other compounds (alprazolam, diazepam,Table 4
Recovery values (%) obtained in different samples at a fortiﬁcation level of 15 mg/kg for solid s
Compound Liquid samples Liq
PFS2 PFS3 PFS4 PFS14 PFS15 PFS16 PFS5 PFS
ESI (+)
Alprazolam 80.2 97.2 77.9 79.6 69.0 69.8 85.0 89.
Amfepramone 122.1 114.6 115.0 126.1 123.3 130.5 110.1 123
Bupropion 110.6 109.2 109.1 110.3 115.3 98.1 109.6 113
Carbamazepine 80.9 85.1 87.8 72.1 82.2 80.2 81.5 89.
Cathine 67.7 86.6 79.9 89.5 72.8 83.2 67.4 71.
Citalopram 76.1 96.6 100.2 109.1 104.4 98.7 83.6 84.
Clobenzorex 74.8 94.6 93.2 83.8 84.1 96.3 83.5 86.
Diazepam 95.6 97.2 86.3 99.5 91.6 88.8 101.4 109
Ephedrine 67.5 92.5 91.5 93.5 79.3 98.9 87.6 102
Fenﬂuramine 103.8 123.2 94.6 114.4 111.8 94.9 106.6 114
Fluoxetine 84.0 80.3 92.9 85.9 105.7 85.9 84.9 89.
Lorazepam 82.7 83.6 84.2 83.6 95.3 92.6 89.6 85.
Mazindol 79.1 108.1 88.1 107.8 100.9 105.8 89.2 84.
Methamphetamine 100.9 96.7 110.9 113.5 96.0 104.3 98.5 106
Norephedrine 61.4 82.8 76.1 87.2 73.4 79.9 67.0 70.
Paroxetine 92.1 94.9 97.2 93.3 103.0 95.9 86.1 84.
Phentermine 94.8 93.7 93.0 112.8 93.6 84.8 103.0 104
Rimonabant 105.1 96.0 90.2 103.7 100.8 87.0 98.2 117
Sertraline 71.4 107.9 88.5 99.7 86.5 94.5 80.5 79.
Subitramine 97.7 102.5 99.5 101.0 111.2 97.2 100.1 93.
Synephrine 67.9 83.3 105.4 67.3 72.7 67.6 60.9 65.
Trazodone 82.6 79.7 88.8 83.3 82.2 86.5 90.4 85.
Venlafaxine 87.9 100.2 100.9 82.4 85.6 82.8 100.5 95.
ESI (−)
Phenolphthaleine 81.9 87.0 79.7 90.9 85.8 86.1 88.7 91.
Topiramate 78.4 86.9 87.0 85.4 96.6 80.4 86.4 80.
Zonisamide 78.0 62.1 83.0 63.0 81.6 81.1 81.0 72.lorazepam and cathine) in PFS speciﬁcally marketed for weight-loss
purposes.
After optimization and validation, the method was successfully ap-
plied to the analysis of sixteen PFS samples comprising different phar-
maceutical forms, namely liquids, ampoules, capsules and tablets.amples and 1.5 mg/l for liquid samples.
uid ampoule samples Tablet Capsule samples Mean
6 PFS11 PFS12 PFS13 PFS7 PFS1 PFS8 PFS9 PFS10
5 84.8 100.1 81.0 82.3 84.9 90.2 81.6 80.1 83.3
.2 121.6 128.0 120.1 106.3 95.1 114.4 107.8 115.3 117.1
.1 105.1 116.0 112.2 117.0 92.4 114.3 121.8 111.9 110.4
0 81.2 84.1 81.5 86.0 93.8 105.9 74.4 103.5 85.6
9 68.3 75.5 98.1 80.1 80.2 66.4 72.9 101.2 78.9
6 63.9 77.6 100.9 87.7 99.2 54.9 81.9 96.1 88.4
4 79.1 82.4 99.8 93.8 88.3 89.3 79.2 94.8 87.7
.7 92.5 110.7 83.6 91.5 83.5 74.5 86.7 103.8 93.6
.2 79.5 71.0 88.1 82.7 77.6 92.2 73.8 112.4 86.9
.3 88.4 106.2 102.3 108.0 95.8 101.5 97.5 113.4 104.8
6 76.2 87.0 84.1 81.5 99.8 108.8 87.9 99.9 89.7
6 79.4 87.2 82.8 85.2 81.1 86.5 78.3 118.6 87.3
0 78.6 88.4 99.0 99.7 97.8 95.7 83.8 81.2 93.0
.9 101.7 107.4 111.6 91.3 91.4 79.8 91.3 116.7 101.2
6 72.3 73.9 88.1 72.8 74.8 67.1 74.8 95.8 76.1
5 85.0 84.6 83.5 84.2 103.3 71.8 75.1 106.9 90.1
.0 100.5 100.6 100.5 86.8 83.6 81.5 83.3 112.7 95.6
.8 95.0 100.9 103.7 83.3 96.9 80.9 103.8 122.8 99.1
3 76.1 76.5 96.4 74.7 88.9 84.4 66.5 96.7 85.5
9 93.1 99.7 88.9 93.9 116.2 89.6 120.5 119.8 101.6
3 70.4 64.3 61.5 67.8 68.2 75.3 61.4 64.3 70.2
9 88.4 79.6 90.1 86.0 88.1 78.6 103.0 109.4 87.7
8 97.4 95.2 86.0 88.3 93.8 87.8 97.4 130.1 94.5
0 72.0 83.6 87.6 85.6 84.7 76.4 82.4 106.2 85.6
8 80.1 86.6 88.2 73.0 81.5 75.3 70.2 108.9 84.1
7 80.4 91.2 88.0 81.5 90.9 67.8 81.5 105.1 80.6
With the exception of synephrine, none of the other 25 drugs was de-
tected in any of the evaluated samples. The presence of synephrine
was conﬁrmed in one sample, codiﬁed as sample PFS12, at a concentra-
tion of 768 μg/l (Fig. 3). This may be related to the composition of the
sample, as indicated in the label (Table S.1), since 135 mg of bitter or-
ange extract (Citrus aurantium amara - button and ﬂower) were de-
clared in the formulation, and synephrine is known to be a natural
constituent of this plant (Di Lorenzo et al., 2014). Bitter orange (Citrus
aurantium L.), or the respective extract, is an ingredient frequently
used in food supplements aimed at reducing body weight due to its
composition in bioactive amines with adrenergic activity, of which
synephrine is the most representative. Both bitter orange and
synephrine are permitted in food supplements, but several countries
have established limits for the content of active amines, in particular
of synephrine, for which the dosage should not exceed 30 mg/day (Di
Lorenzo et al., 2014). The determined content of synephrine, corre-
sponding to 7.7 μg per ampoule, is much below this limit. Considering
the low content of this compound, its presence in the sample is most
probably explained by the use of the plant extract and not by the addi-
tion of synephrine and therefore should not be considered neither as a
fraud or mislabelling.
Compared to previous studies on PFS adulteration, the obtained re-
sultswere identical to those of Choi et al. (2015)who also did not detect
any of the 28 narcotic adulterants analysed in 47 dietary supplements
purchased in South Korea. By the contrary, recently, Hachem et al.
(2016) analysed 160 PFS marketed for weight-loss by using Proton
NMR and found that 43 samples contained the anorexic sibutramine,
9 samples contained phenolphthalein, 23 samples a mixture of
sibutramine and phenolphthalein, 12 samples sildenaﬁl (a drug for
erectile dysfunction), 4 samples the antidepressant ﬂuoxetine, 1 sample
the anorexic orlistat and 1 samples contained the anorexic lorcaserine. A
high level of adulteration in weight-loss PFS was also described by
Reeuwijk et al. (2014) which reported that 24 out of 50 PFS acquired
in 2004 and 2010–2013 were adulterated with sibutramine,Fig. 3. Chromatograms of the PFS sample positive for synephririmonabant, sildenaﬁl and phenolphthalein and by Johansson et al.
(2014) which detected different adulterants (sibutramine, orlistat, sil-
denaﬁl, ﬂuoxetine and/or yohimbine) in 21 out of 43 weigh-loss PFS.
In both cases, the high level of adulterations found could be related to
the sampling strategy since in the study of Reeuwijk et al. (2014) PFS
were sampled by inspectors of the Netherlands Food and Consumer
Product Safety Authority, which collected products based on experi-
ence, reports and alerts, and in the study of Johansson et al. (2014) sam-
ples were collected from the illegal market within projects performed
together with the Swedish police and/or customs. Slightly lower levels
of adulteration in weight-loss PFS were reported by Zeng et al. (2016),
namely 119 samples out of 447, albeit samples also included PFS seized
during enforcement operations. A signiﬁcantly lower number of adul-
terated PFS (4 out of 106) was reported by Carvalho et al. (2011)
when analysing weight-loss PFS sold by compounding pharmacies in
Brazil.
4. Conclusions
A method based on QuEChERS extraction and UHPLC-MS/MS was
successfully developed and validated for the analysis of 26 pharmaceu-
tical compounds belonging to different therapeutic classes (anorexics,
stimulants, anxiolytics, antidepressants and laxatives), which are all
prone to be illegally added into weight-loss PFS for their pharmacolog-
ical activity. Internal standard calibration with six isotopically labelled
compounds rendered good linearity and sensitivity with LOQs in the
range of 0.02–9.80 μg/l. Matrix effects and recoveries were assessed
for all the 16 samples analysed and were found between 70% and
120% for over 90% of the analytes. The changes introduced to the
QuEChERS procedure maintained the good performance characteristics
of the extractionmethodwhile preserving the chromatographic system
for the introduction of unwanted matrix compounds. Synephrine was
the only compound detected and quantiﬁed in one sample, but at a
very low concentration (768 μg l−1) and its presence may be due tone (PFS12) and a synephrine standard solution (250 μg/l).
the plant extracts used in the formulation, as synephrine is known to be
a natural constituent of Citrus aurantium amara. Despite none of the 16
evaluated samples were found to be adulterated by the illegal addition
of the drugs included in this work, the developed methodology can be
very useful for monitoring the adulteration of weight-loss PFS.
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